Scientia Ventures

knowledge is power

In short

Intelligent Investment in Healthcare

In Numbers

31 Companies Funded

5 IPOs



Latest Press

1910 Genetics Debuts with $26M to Accelerate the Design of Small Molecule and Protein Therapeutics Through AI, Computation and Biological Automation

FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million

Cibus Achieves Critical Milestones for Two New Gene-Edited Traits that Increase Productivity for Rice Farmers


Royalty Pharma

Transforming the funding of life sciences through collaborative capital, Royalty Pharma developed and is the leader in the pharmaceutical royalty business.


ADC Therapeutics

ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates for the treatment of both solid and hematological cancers.


Intra-Cellular Therapies

Intra-Cellular Therapies is a leading biopharmaceutical company founded by Nobel Prize winner: Paul Greengard...